ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Tuesday, October 28, 2025

10:30AM-12:30PM
Abstract Number: 2162
An Updated Needs Assessment for the Virtual Rheumatology Program for Fellows in Training (V-FIT)
(2159–2194) Professional Education Poster
10:30AM-12:30PM
Abstract Number: 2242
Analysis of Bronchoalveolar Fluid Cytokine Profile as a Way to Understand the Lung Disease Associated with Systemic Juvenile Idiopathic Arthritis
(2227–2264) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III
10:30AM-12:30PM
Abstract Number: 2395
Analysis of histopathological changes in the placenta of patients with systemic lupus erythematosus
(2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III
10:30AM-12:30PM
Abstract Number: 1934
Analysis of the Determinants of Vaccine Acceptance and Hesitancy in Germany: A Mixed-Methods Approach Incorporating Health Insurance Data and Qualitative Interviews with Patients and Physicians
(1914–1935) Health Services Research Poster III
10:30AM-12:30PM
Abstract Number: 2397
Analytical Performance of a Fully Automated Multiplexed Microarray Immunoassay for the Simultaneous Detection of Fifteen Autoantibodies Associated with Connective Tissue Diseases in a Reference Laboratory in Southern France
(2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III
10:30AM-12:30PM
Abstract Number: 2398
Analytical performance of the HEp-2 substrate Diagnostic Kit for ANA as an initial step in the evaluation of a novel Fully Automated IFA Analyzer in a laboratory in England
(2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III
10:30AM-12:30PM
Abstract Number: 2120
Analyzing Gender and Racial Disparities in Paget’s Disease of Bone: A Large-Scale Observational Study
(2106–2123) Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster II
10:30AM-12:30PM
Abstract Number: 2417
Anti-dense fine speckled 70 antibodies in undefined disease, systemic autoimmune rheumatic diseases and controls
(2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III
10:30AM-12:30PM
Abstract Number: 2386
Anti-Trim72 Auto-antibodies In Systemic Lupus Erythematosus Patients and a Lupus Mouse Model with Myocarditis Compromise Membrane Repair in Mouse & Human Cardiomyocytes
(2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III
10:30AM-12:30PM
Abstract Number: 1858
Antinuclear Antibodies from Systemic Sclerosis Patients Enter Cells via a Clathrin Endocytosis Mechanism and Interact with their Intracellular Antigen.
(1855–1876) Systemic Sclerosis & Related Disorders – Basic Science Poster II
10:30AM-12:30PM
Abstract Number: 2391
Antinuclear Antibody Positivity in Patients with Psoriasis and Psoriatic Arthritis and the Risk of Developing Clinical Symptoms of SLE Following TNF Inhibitor Therapy
(2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III
10:30AM-12:30PM
Abstract Number: 2283
Arrhythmia Risk in Diabetic Rheumatoid Arthritis Patients: Comparative Analysis of IL-6 Inhibitors versus TNF-α Inhibitors
(2265–2289) Rheumatoid Arthritis – Treatment Poster III
10:30AM-12:30PM
Abstract Number: 2565
Assessing Participation in the Lupus Sister Circle Support Group
(2547–2566) ARP Posters I
10:30AM-12:30PM
Abstract Number: 1898
Assessing Representation in a Nation-Wide Psoriasis Registry: A Single-Institution Comparison
(1877–1913) Epidemiology & Public Health Poster III
10:30AM-12:30PM
Abstract Number: 1966
Assessing the Impact of Cutaneous Melanin on Microvascular Oxygenation Measurement in Systemic Sclerosis Using Multispectral Imaging
(1936–1971) Imaging of Rheumatic Diseases Poster
  • «Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 62
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology